WallStSmart

IQVIA Holdings Inc (IQV)vsThermo Fisher Scientific Inc (TMO)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Thermo Fisher Scientific Inc generates 166% more annual revenue ($45.20B vs $16.98B). TMO leads profitability with a 15.1% profit margin vs 8.1%. IQV appears more attractively valued with a PEG of 0.98. TMO earns a higher WallStSmart Score of 59/100 (C).

IQV

Buy

55

out of 100

Grade: C

Growth: 4.0Profit: 6.5Value: 6.7Quality: 3.0
Piotroski: 2/9Altman Z: 1.23

TMO

Buy

59

out of 100

Grade: C

Growth: 4.7Profit: 7.0Value: 4.0Quality: 6.0
Piotroski: 3/9Altman Z: 2.13
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

IQVUndervalued (+11.9%)

Margin of Safety

+11.9%

Fair Value

$201.09

Current Price

$228.20

$27.11 discount

UndervaluedFair: $201.09Overvalued
TMOSignificantly Overvalued (-72.9%)

Margin of Safety

-72.9%

Fair Value

$333.36

Current Price

$564.75

$231.39 premium

UndervaluedFair: $333.36Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

IQV2 strengths · Avg: 8.5/10
Return on EquityProfitability
22.3%9/10

Every $100 of equity generates 22 in profit

PEG RatioValuation
0.988/10

Growing faster than its price suggests

TMO2 strengths · Avg: 8.5/10
Market CapQuality
$194.53B9/10

Large-cap with strong market position

Free Cash FlowQuality
$1.68B8/10

Generating 1.7B in free cash flow

Areas to Watch

IQV4 concerns · Avg: 2.8/10
P/E RatioValuation
29.2x4/10

Moderate valuation

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

EPS GrowthGrowth
-0.6%2/10

Earnings declined 0.6%

Altman Z-ScoreHealth
1.232/10

Distress zone — elevated risk

TMO3 concerns · Avg: 3.7/10
PEG RatioValuation
1.734/10

Expensive relative to growth rate

P/E RatioValuation
28.8x4/10

Moderate valuation

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : IQV

The strongest argument for IQV centers on Return on Equity, PEG Ratio. PEG of 0.98 suggests the stock is reasonably priced for its growth.

Bull Case : TMO

The strongest argument for TMO centers on Market Cap, Free Cash Flow. Profitability is solid with margins at 15.1% and operating margin at 17.9%.

Bear Case : IQV

The primary concerns for IQV are P/E Ratio, Piotroski F-Score, EPS Growth. Debt-to-equity of 2.58 is elevated, increasing financial risk.

Bear Case : TMO

The primary concerns for TMO are PEG Ratio, P/E Ratio, Piotroski F-Score.

Key Dynamics to Monitor

IQV profiles as a value stock while TMO is a mature play — different risk/reward profiles.

IQV carries more volatility with a beta of 1.20 — expect wider price swings.

IQV is growing revenue faster at 8.7% — sustainability is the question.

TMO generates stronger free cash flow (1.7B), providing more financial flexibility.

Bottom Line

TMO scores higher overall (59/100 vs 55/100), backed by strong 15.1% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

IQVIA Holdings Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

IQVIA, formerly Quintiles and IMS Health, Inc., is an American multinational company serving the combined industries of health information technology and clinical research. It is a provider of biopharmaceutical development and commercial outsourcing services, focused primarily on Phase I-IV clinical trials and associated laboratory and analytical services, including consulting services.

Thermo Fisher Scientific Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Thermo Fisher Scientific is an American provisioner of scientific instrumentation, reagents and consumables, and software and services to healthcare, life science, and other laboratories in academia, government, and industry (including in the biotechnology and pharmaceutical sectors). Based in Waltham, Massachusetts, Thermo Fisher was created in 2006 by the merger of Thermo Electron and Fisher Scientific, to form a company with US$ 9 billion in combined revenues.

Visit Website →

Want to dig deeper into these stocks?